CHARACTERIZATION OF BRUCELLOSIS

布鲁氏菌病的特征

• 批准号: 8172720
• 负责人: Jean L. Patterson
• 金额: $ 17.27万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172720
• 关键词: Affect; Animal Model; Animals; Attenuated; Attenuated Live Virus Vaccine; Bacteria; Brucella; Brucella melitensis; Brucellosis; California; Categories; Cavia; Chronic; Computer Retrieval of Information on Scientific Projects Database; Disadvantaged; Disease Progression; Funding; Genetic; Goals; Grant; Granulomatous; Human; Immune; Immune response; Immunologic Markers; Inbred Strain; Infection; Institution; Macaca mulatta; Modeling; Mus; National Institute of Allergy and Infectious Disease; Organism; Pathogenicity; Pathologic; Physiology; Reagent; Research; Research Personnel; Resources; Source; Texas; United States National Institutes of Health; Vaccines; Virulent; nonhuman primate; pathogen; pre-clinical research; transmission process; vaccine development; weapons

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Brucellosis is a chronic granulomatous infection caused by several subtypes of the intracellular bacteria Brucella. There are less than 100 cases/year of natural brucellosis in USA, which occur predominantly in California and Texas; however, due to the possibility of airborne transmission of this pathogen, Brucella is considered a potential biologic weapon (NIAID category B agent). A human vaccine has not been developed for brucellosis, and some of the successful live-attenuated vaccines (LAV) used in animals still retain pathogenicity for humans. A major difficulty affecting the development of a vaccine against human brucellosis is the absence of well-established immune correlates of protection. Pathogenicity varies among Brucella species in all mammalian species evaluated. The mouse and guinea pig model of human vaccine development have the disadvantage of using inbred strains and consequent limited generalization of the results, and low availability of reagents for a thorough characterization of the immune response to the vaccines, respectively. Nonhuman primates (NHP) are the preferred animal models for pre-clinical research because they approximate humans in physiology and genetics more closely than any other animal. NHP are susceptible to infection with virulent or attenuated strains of Brucella organisms, and recent studies have shown that rhesus macaques infected with B. melitensis 16 M develop pathologic changes similar to the ones observed in human brucellosis. The immediate goal of this project is to define the rhesus macaque model for brucellosis and to identify potential immune markers of disease progression and protection.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 布鲁氏菌病是一种慢性肉芽肿性感染，由细胞内布鲁氏菌的几种亚型引起。 在美国，每年自然发生的布鲁氏菌病病例不到100例，主要发生在加州和德克萨斯州;然而，由于该病原体可能通过空气传播，布鲁氏菌被认为是一种潜在的生物武器（NIAID B类病原体）。 布鲁氏菌病的人用疫苗尚未开发出来，一些成功用于动物的减毒活疫苗（LAV）仍保留对人类的致病性。 影响人类布鲁氏菌病疫苗开发的主要困难是缺乏完善的免疫保护相关物。 在评价的所有哺乳动物种属中，布鲁氏菌种属间的致病性各不相同。人用疫苗开发的小鼠和豚鼠模型分别具有以下缺点：使用近交系，结果的推广有限，以及用于彻底表征对疫苗的免疫应答的试剂的可用性低。 非人灵长类动物（NHP）是临床前研究的首选动物模型，因为它们在生理学和遗传学上比任何其他动物更接近人类。 NHP对布鲁氏菌有机体的强毒株或减毒株感染敏感，最近的研究表明，感染B.羊种布氏杆菌16 M产生与在人类布氏杆菌病中观察到的相似的病理变化。 该项目的近期目标是确定布鲁氏菌病的恒河猴模型，并确定疾病进展和保护的潜在免疫标志物。